Rosenstock AS, et al. - This research was designed in order to assess the risk of developing acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after modern adjuvant chemotherapy in older breast cancer patients. It also involved an additional definition of the risk of individual chemotherapy regimens. The findings brought to light the link between adjuvant chemotherapy with a minor yet notable rise in the risk of AML and MDS, particularly with anthracycline (A). In order to affirm that risk did not rise with the recently adopted docetaxel and cyclophosphamide (TC) regimen, further studies were required.